Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Dec 8;7(3):624-628.
doi: 10.1016/j.ekir.2021.11.036. eCollection 2022 Mar.

Compassionate Use of Avacopan in Difficult-to-Treat Antineutrophil Cytoplasmic Antibody-Associated Vasculitis

Jolijn R van Leeuwen  1 , Obbo W Bredewold  1 , Laura S van Dam  1 , Stella L Werkman  1 , Jacqueline T Jonker  1   2 , Miranda Geelhoed  3 , Antonius P M Langeveld  4 , Hilde H F Remmelts  5 , Maud M van den Broecke  1 , Argho Ray  1 , Ton J Rabelink  1 , Y K Onno Teng  1
Affiliations

Compassionate Use of Avacopan in Difficult-to-Treat Antineutrophil Cytoplasmic Antibody-Associated Vasculitis

Jolijn R van Leeuwen et al. Kidney Int Rep. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Treatment outcomes. (a) Disease course per patient in relation to start of avacopan (black line). Columns start at moment of diagnoses and end at current date or stop of avacopan (x). Note that the x-as changes at −1 yr (dotted line) from 6 yr to 6 mo per thick. For some periods of time, it could not be reconstructed if or when remission was achieved (unknown disease activity). ∗Reduction of avacopan dosing to 20 mg twice a day. (b) BVAS per patient at different time points. (c) Prednisone dosage in mg/d per patient at different time points. (d) Composite items of GTI. Per patient is revealed when the item was affected at the start of avacopan and the GTI index is scored after 1 yr of avacopan use. Scores can range from −36 to 439, with increasing scores relating to an increase in glucocorticoid toxicity burden and negative scores reflecting an improvement in toxicity. Last row is total affected items and total GTI score. BMI, body mass index; BVAS, Birmingham vasculitis activity score; GTI, Glucocorticoid Toxicity Index; mo, month; N/A, not applicable; Tot, total; yr, year.
See this image and copyright information in PMC

References

    1. Jayne D.R.W., Bruchfeld A.N., Harper L., et al. Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis. J Am Soc Nephrol. 2017;28:2756–2767. doi: 10.1681/ASN.2016111179. - DOI - PMC - PubMed
    1. Merkel P.A., Niles J., Jimenez R., et al. Adjunctive treatment with avacopan, an oral C5a receptor inhibitor, in patients with antineutrophil cytoplasmic antibody-associated vasculitis. ACR Open Rheumatol. 2020;2:662–671. doi: 10.1002/acr2.11185. - DOI - PMC - PubMed
    1. Jayne D.R.W., Merkel P.A., Schall T.J., Bekker P., ADVOCATE Study Group Avacopan for the treatment of ANCA-associated vasculitis. N Engl J Med. 2021;384:599–609. doi: 10.1056/NEJMoa2023386. - DOI - PubMed
    1. Inacio P. FDA Approves Tavneos as Add-on Therapy for Severe MPA, GPA. ANCA Vasculitis News. https://ancavasculitisnews.com/2021/10/11/fda-approves-tavneos-avacopan-... Published October 11, 2021. Accessed October 29, 2021.
    1. Wexler M. EU Committee Recommends Approval of Tavneos for Severe, Active AAV. ANCA Vasculitis News. https://ancavasculitisnews.com/2021/11/15/eu-committee-chmp-recommends-a... Published November 15, 2021. Accessed November 19, 2021.

LinkOut - more resources